Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...

Vitiligo is believed to be an autoimmune condition where the body attacks its own healthy melanin-producing skin cells by mistake. It may be hereditary or triggered by a particular event like ...